Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin

Archives of Ophthalmology
J W MillerE S Gragoudas

Abstract

To investigate photodynamic therapy of experimental choroidal neovascularization using benzoporphyrin derivative monoacid (Verteporfin). Photodynamic therapy using benzoporphyrin derivative monoacid was investigated in cynomolgus monkeys. Following intravenous injection of benzoporphyrin derivative monoacid (1 to 2 mg/kg) complexed with low-density lipoprotein, the eyes were irradiated with 692-nm light at a fluence of 50 to 150 J/cm2 and irradiance of 150 to 600 mW/cm2. Choroidal neovascularization was documented before photodynamic therapy and closure was demonstrated by fundus photography, fluorescein angiography, and light and electron microscopic examination. Following photodynamic therapy, vessels within choroidal neovascularization were occluded, and there was damage to the choroidal neovascularization endothelium and the subjacent choriocapillaris. Damage to the retinal pigment epithelium and photoreceptors was also observed. Photodynamic therapy with lipoprotein-delivered benzoporphyrin derivative monoacid was effective in this animal model of choroidal neovascularization and may be a promising, potentially selective, therapy for choroidal neovascularization.

Citations

Aug 25, 2001·The British Journal of Ophthalmology·U E SchnurrbuschS Wolf
Sep 24, 2010·Journal of Lipid Research·Steven J Fliesler, Lionel Bretillon
Aug 24, 2004·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·J WachtlinM H Foerster
Jan 20, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Stefan MennelGabriele Thumann
Mar 8, 2013·Photodiagnosis and Photodynamic Therapy·Mathias O Senge, Marek W Radomski
Mar 19, 2011·Experimental Eye Research·Robin J GoodyMatthew S Lawrence
Apr 22, 2015·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Igor Kozak, Jeffrey K Luttrull
Jan 25, 2007·Acta Ophthalmologica Scandinavica·Gianni VirgiliUgo Menchini
May 6, 2004·American Journal of Ophthalmology·Timothy Y Y LaiDennis S C Lam
Jul 11, 2006·Experimental Eye Research·Taisaku FunakoshiRobert J D'Amato
Oct 9, 2001·American Journal of Ophthalmology·R A CostaJ A Cardillo
Oct 21, 2000·Experimental Eye Research·J L Edelman, M R Castro
Dec 24, 2002·Biophysical Journal·Stéphanie BonneauDaniel Brault
Mar 8, 2000·American Journal of Ophthalmology·M S BlumenkranzR Miller
Oct 24, 2001·Advanced Drug Delivery Reviews·R Z Renno, J W Miller
Aug 23, 2006·Annual Review of Medicine·Edwin M Stone
Oct 5, 2007·Annual Review of Pharmacology and Toxicology·Gary D Novack
Jan 27, 2000·Ophthalmology·G A PeymanD M Moshfeghi
May 1, 2004·Photodiagnosis and Photodynamic Therapy·D Kessel
Apr 27, 2017·Journal of Lipid Research·Seyedeh Maryam ZekavatNorman A Mazer

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.